UBS raised the firm’s price target on Quest Diagnostics (DGX) to $180 from $175 and keeps a Neutral rating on the shares. UBS says Quest’s Q2 results were “good enough.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $192 from $190 at Truist
- Quest Diagnostics price target raised to $178 from $160 at Deutsche Bank
- Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating
- Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating
- Quest Diagnostics Reports Strong Q2 2025 Results